Mutations in FLT3, IDH1, and IDH2 encompass 25% of elderly patients with AML, and therapies directed at these mutations (gilteritinib [5], ivosidenib [6], and enasidenib [7], respectively) mediate differentiation as their primary mechanism of action. This evidence concerns the gene FLT3 and acute myeloid leukemia.